T ype III interferons (IFN-λ) are members of the interferon (IFN) family and critical mediators of antiviral defenses [1] [2] [3] . IFN-λ family members have functions similar to type I IFN, and are structurally related to the IL-10 cytokine family, utilizing the IL-10R2 receptor subunit as a part of their heterodimeric receptor with IFN-λR1 chain 4 . Although IFN-λ has overlapping functions with type I IFNs, several studies have revealed a unique, non-redundant role for IFN-λ in mediating protection against disease and pathology in the liver and at mucosal and barrier surfaces [5] [6] [7] [8] [9] [10] . Influenza A virus (IAV) is a respiratory pathogen that causes seasonal epidemics and also presents the potential for major pandemic outbreaks and global disease through continual emergence and reemergence from avian reservoirs. The high incidence of IAV infection, coupled with low vaccine effectiveness during the 2017-2018 season, highlights the necessity to gain a better understanding of the processes that regulate the immune responses against infection, to guide efforts aimed at developing effective therapeutic and vaccine adjuvants to protect against infection 11 . As an innate immune and immune-regulatory cytokine, IFN-λ has the capacity to direct protective immunity against IAV infection. When administered intranasally following IAV challenge, IFN-λ restricts IAV infection without inducing excessive tissue damaging inflammation that is typically associated with type I IFN administration [12] [13] [14] [15] . The protective and non-injurious effects of IFN-λ are attributed, in part, to the selective expression of IFN-λR1 compared to the broad expression of the type I IFN receptor (IFNAR), wherein IFN-λR1 is selectively expressed on epithelial cells, neutrophils, plasmacytoid dendritic cells and, potentially, natural killer (NK) cells that contribute to IAV immunity 12, 13, [16] [17] [18] [19] [20] . Although IFN-λ directs innate immune defenses that can restrict IAV infection, the contribution of IFN-λ signaling to adaptive immunity is less clear [21] [22] [23] . IFN-λ has been shown to enhance type I helper T cell responses in the lung, suggesting it has a role in regulating immune polarization during IAV infection 21, 22 . Despite these observations, the direct function of IFN-λ on programming and maintenance of adaptive immune responses during IAV infection remains largely unknown. Here, we utilized murine infection models to investigate the role of IFN-λ (of which IFN-λ2 and IFN-λ3 are conserved between mice and humans) in adaptive immunity against IAV. We demonstrate that IFN-λ signaling is critical for the development of virus-specific CD8 + T cells and generation of protective immunity that is able to provide cross-protection against heterosubtypic IAV re-challenge. We found that the blunted CD8 + T cell response in IFN-λ receptor-deficient (Ifnlr1 −/− ) mice is due to a defect in the activation, migration and function of dendritic cells (DCs), linked with aberrant expression of a DC-derived IL-10 immunoregulatory gene network. IFN-λ specifically programs migratory, antigen-presenting CD103 + DCs to mediate CD8 + T cell activation for broad protection against IAV infection and for heterosubtypic virus challenge that underscores contemporary IAV outbreaks in humans. Thus, IFN-λ, through the recruitment and function of CD103 + DCs and regulation of IL-10 production, is an essential component of effective immunity against IAV infection and for cross-protection against heterosubtypic IAV emergence.
T ype III interferons (IFN-λ) are members of the interferon (IFN) family and critical mediators of antiviral defenses [1] [2] [3] . IFN-λ family members have functions similar to type I IFN, and are structurally related to the IL-10 cytokine family, utilizing the IL-10R2 receptor subunit as a part of their heterodimeric receptor with IFN-λR1 chain 4 . Although IFN-λ has overlapping functions with type I IFNs, several studies have revealed a unique, non-redundant role for IFN-λ in mediating protection against disease and pathology in the liver and at mucosal and barrier surfaces [5] [6] [7] [8] [9] [10] . Influenza A virus (IAV) is a respiratory pathogen that causes seasonal epidemics and also presents the potential for major pandemic outbreaks and global disease through continual emergence and reemergence from avian reservoirs. The high incidence of IAV infection, coupled with low vaccine effectiveness during the 2017-2018 season, highlights the necessity to gain a better understanding of the processes that regulate the immune responses against infection, to guide efforts aimed at developing effective therapeutic and vaccine adjuvants to protect against infection 11 .
As an innate immune and immune-regulatory cytokine, IFN-λ has the capacity to direct protective immunity against IAV infection. When administered intranasally following IAV challenge, IFN-λ restricts IAV infection without inducing excessive tissue damaging inflammation that is typically associated with type I IFN administration [12] [13] [14] [15] . The protective and non-injurious effects of IFN-λ are attributed, in part, to the selective expression of IFN-λR1 compared to the broad expression of the type I IFN receptor (IFNAR), wherein IFN-λR1 is selectively expressed on epithelial cells, neutrophils, plasmacytoid dendritic cells and, potentially, natural killer (NK) cells that contribute to IAV immunity 12, 13, [16] [17] [18] [19] [20] . Although IFN-λ directs innate immune defenses that can restrict IAV infection, the contribution of IFN-λ signaling to adaptive immunity is less clear [21] [22] [23] . IFN-λ has been shown to enhance type I helper T cell responses in the lung, suggesting it has a role in regulating immune polarization during IAV infection 21, 22 . Despite these observations, the direct function of IFN-λ on programming and maintenance of adaptive immune responses during IAV infection remains largely unknown. Here, we utilized murine infection models to investigate the role of IFN-λ (of which IFN-λ2 and IFN-λ3 are conserved between mice and humans) in adaptive immunity against IAV. We demonstrate that IFN-λ signaling is critical for the development of virus-specific CD8
+ T cells and generation of protective immunity that is able to provide cross-protection against heterosubtypic IAV re-challenge. We found that the blunted CD8 + T cell response in IFN-λ receptor-deficient (Ifnlr1 −/− ) mice is due to a defect in the activation, migration and function of dendritic cells (DCs), linked with aberrant expression of a DC-derived IL-10 immunoregulatory gene network. IFN-λ specifically programs migratory, antigen-presenting CD103 + DCs to mediate CD8 + T cell activation for broad protection against IAV infection and for heterosubtypic virus challenge that underscores contemporary IAV outbreaks in humans. Thus, IFN-λ, through the recruitment and function of CD103 + DCs and regulation of IL-10 production, is an essential component of effective immunity against IAV infection and for cross-protection against heterosubtypic IAV emergence.
Results

IFN-λ signaling is required to generate protective memory T cell responses.
To assess the role of IFN-λ signaling downstream of IFN-λR1 in controlling protection against secondary IAV infection we examined the response to heterosubtypic IAV challenge and determined the ability of Ifnlr1 −/− mice to mount a protective homosubtypic and heterosubtypic (T cell-dependent) memory response against IAV infection. We interrogated both homo-and heterosubtypic re-challenge, as neutralizing antibody responses have been demonstrated to effectively prevent homosubtypic IAV infection, but heterosubtypic IAV infection is a common occurrence −/− X31-PR8 to WT X31-PR8 was determined using log-rank test. NS, not significant (P = 0.3720), *P < 0.01. . (a,b) . Significance was determined using one-way ANOVA followed by Tukey's multiple comparisons test between WT D35 and Ifnlr1 −/− D35. *P < 0.05, **P < 0.001.
Interferon-λ modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus
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Nature ImmuNology in humans and other susceptible species during pandemic and seasonal outbreaks caused by exposure to related heterosubtypic IAV strains of a different hemagglutinin (HA) subtype. It has been established in mouse models of heterosubtypic IAV re-challenge, as well as during human infection, that neutralizing antibody responses are not effective at preventing heterosubtypic IAV infection and disease [24] [25] [26] . In contrast, CD8 + T cells are critical mediators of protection against heterosubtypic IAV infection while antibodies are dispensible 24, [27] [28] [29] . As in previous heterosubtypic IAV challenge studies of mice, we mock-infected animals, challenged them with a low dose of murine-adapted IAV A/PR/8/34 (IAV-PR8) that leads to clinical respiratory illness and weight loss with complete survival and recovery 30, 31 or challenged with an equivalent infectious dose of recombinant H3N2 IAV containing the hemagglutinin (HA) and neuraminidase (NA) of A/HK/1/68 and the remaining segments from IAV-PR8 (IAV-X31). The dose of IAV-PR8 utilized consistently lead to a minor, yet statistically significant, increase in virus titers, and caused similar weight loss and respiratory illness, but no lethality, in wild-type (WT) and Ifnlr1 −/− mice, as described by others 13, 15, 32 ( Supplementary Fig. 1 ). On day 45 following initial infection, all mice were challenged with a completely lethal dose for naive mice of 2,000 plaque-forming units (PFU) IAV-PR8 (Fig. 1a) , thus modeling IAV cross-exposure that occurs during seasonal epidemics. Both wild-type and Ifnlr1 −/− mice succumbed to secondary infection following mock primary infection, while prior exposure to IAV-PR8 provided immune memory that protected against disease (Fig. 1b-d) . Antibodies probably contribute to this protection against the homologous 2,000 PFU challenge, as we observed Fig. 2 ). Prior infection with IAV-X31 resulted in weight loss and illness but no change in overall susceptibility to IAV-PR8 heterosubtypic infection in wild-type mice (Fig. 1b-d) . Importantly, Ifnlr1 −/− mice previously infected with IAV-X31 were increasingly susceptible to IAV-PR8 heterosubtypic infection and exhibited a significant reduction in survival concomitant with accelerated and prolonged weight loss and disease symptoms, with a significant increase in illness score in Ifnlr −/− mice on days 2-5 post-heterosubtypic IAV challenge compared to wild type (Fig. 1b-d) . These results indicate that IFN-λ signaling is critical in generating T cell-mediated cross-protective immunity against heterologous IAV infection.
To determine whether populations of IAV-specific T cells were functionally altered in Ifnlr1 −/− mice compared to wild type at a memory time point (day 35 post-infection) following IAV infection, we challenged wild-type and Ifnlr1
−/− mice with IAV-PR8 and assessed T cell responses in lung-draining mediastinal lymph nodes (dLN) on day 35 post-infection. We observed a significant reduction in the frequency and numbers of IAV-specific CD4 + and CD8 + T cells in dLN of Ifnlr1 −/− mice compared to wild type on day 35 post-infection (Fig. 2a,b) . These results suggest that insufficient memory T cells likely account for the enhanced susceptibility of Ifnlr1 −/− mice on heterosubtypic virus secondary challenge.
IFN-λ signaling is essential for development of the IAV-specific CD8 + T cell response. To determine the role of IFN-λ signaling in programming the effector T cell response against IAV infection, we measured the IAV-specific CD8 + T cell response in the lungs of wild-type and Ifnlr1 −/− mice following IAV infection. On day 9 post-infection, the frequency and numbers of CD8 + T cells specific to the IAV immunodominant nucleoprotein (NP 366 ) epitope were significantly reduced in Ifnlr1 −/− animals compared to wild type (Fig. 3a) . Additionally, the lung CD8 + T cells displayed reduced amounts of IFN-γ and TNF production in Ifnlr1 −/− compared to wild-type mice during IAV infection (Fig. 3b-d) . A similar, significant reduction in the polymerase acid (PA 224 )-specific response of Ifnlr1 −/− mice infected with IAV was also observed (data not shown). 
(IAV). f, WT and Ifnlr1
−/− BMDCs were incubated with 10 μg ml −1 DQ-OVA for 30 min, 1 h or 2 h at 37° C, or 2 h on ice, and uptake of DQ-OVA was measured using flow cytometry. One representative of three independent experiments shown, where n = 3. Mean ± s.d. shown. Statistical significance determined using an unpaired two-sided t-test comparing WT and Ifnlr1 −/− (b,d) and using one-way ANOVA and Tukey's multiple comparisons test (c). *P < 0.05, **P < 0.001, ***P < 0.0001.
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In contrast, no difference in the frequency or numbers of IAVspecific CD4 + T cells, or their cytokine production following stimulation with NP 311 IAV peptide ex vivo, was found between wild-type and Ifnlr1 −/− mice on day 9 post-infection ( Supplementary Fig. 3 ). Together, these findings identify a requirement for IFN-λ signaling in the generation of an optimal IAV-specific CD8 + T cell response.
IFN-λ signaling in DCs is important for function and priming of IAV-specific CD8
+ T cells. Previous studies have shown that T cells lack IFN-λ receptor expression and do not respond directly to IFN-λ 23 . However, given the defect in the IAV-specific CD8 + T cell response in Ifnlr1 −/− mice, we opted to assess whether IFN-λ signaling, intrinsic or extrinsic to CD8 + T cells, was responsible for the aberrant CD8
+ T cell response in the Ifnlr1 −/− mice. Stimulation of lung homogenates with phorbol 12-myristate 13-acetate (PMA) and ionomycin yielded equivalent amounts of IFN-γ and TNF produced by wild-type and Ifnlr1
−/− CD8 + T cells ( Fig. 3b-d ), suggesting that CD8 + T cells are fully capable of producing these cytokines in the absence of Ifnlr1 and IFN-λ signaling. Furthermore, we purified CD8 + T cells from the spleens of wildtype and Ifnlr1 −/− mice and stimulated them with plate-bound α-CD3/CD28. Both wild-type and Ifnlr1
−/− CD8 + T cells underwent robust cell division and expressed the activation markers CD44 and CD69 when stimulated ex vivo (Fig. 4a) . Thus, the defect in the activation of the IAV-specific CD8
To verify that the defect in the IAV-specific CD8 + T cell response was due to a T cell-extrinsic effect that impacts T cell activation and functional differentiation, we transferred wild-type, carboxyfluorescein succinimidyl ester (CFSE)-labeled, glycoprotein (GP 33 )-specific CD8
+ T cells expressing a disparate CD45 molecule into wild-type and Ifnlr1 −/− mice, and infected the mice with IAV-PR8 containing a GP 33 epitope. After 3.5 days in Ifnlr1 −/− hosts, the average number of divisions that activated GP 33 -specific CD8 + T cells had undergone was significantly reduced in dLN compared to GP 33 -specific CD8
+ T cells transferred to WT mice (Fig. 4b) . Together, these results demonstrate that the defect in the CD8 + T cell response against IAV occurs early, at the time of antigen priming, and is caused by a T cell-extrinsic process in Ifnlr1 −/− mice.
IFN-λ signaling in DCs is required for their function and migration to dLN following IAV infection.
To determine whether a defect in DC function could be responsible for the aberrant CD8
we evaluated the responses of wildtype and Ifnlr1
−/− bone marrow-derived DCs (BMDCs) to several stimuli. We found that BMDCs expressed Ifnlr1 messenger RNA with increasing levels on IAV infection, in contrast to their levels of Ifnar1 expression, which was similar in both wild-type and Ifnlr1
BMDCs, irrespective of infection (Fig. 4c) . Stimulation of BMDCs with 500 ng IFN-λ3 or 10 ng IFN-α2 lead to similar phosphorylation of the transcription factor STAT1, which is downstream of IFN-λR1 ( Supplementary Fig. 4a ), and BMDCs responded to IFN-λ in a dose-dependent manner ( Supplementary Fig. 4b ), indicating that BMDCs respond directly to IFN-λ stimulation. Furthermore, these BMDCs expressed interferon-stimulated genes (ISGs) 12 h following treatment with IFN-λ3 ( Supplementary Fig. 4c ). However, we found that Ifnlr1 −/− BMDCs were unable to increase CD40 surface protein expression following IAV infection (Fig. 4d) . These changes in activation on infection were not due to changes in viral burden in BMDCs, as wild-type and Ifnlr1 −/− BMDCs expressed similar levels of IAV NP at this time following infection (Fig. 4e) . Furthermore, the ability of Ifnlr1 −/− BMDCs to uptake and process antigen, as measured by DQ ovalbumin (DQ-OVA) fluorescence, was reduced compared to wild-type BMDCs (Fig. 4f) . Thus, IFN-λ signaling is intact in BMDCs and is essential for DC maturation and function following IAV infection.
To determine whether DC responses were defective in vivo in Ifnlr1 −/− mice, we assessed the ability of DCs to migrate from the lungs to dLN. CFSE was administered intranasally to the lungs of wild-type and Ifnlr1 −/− mice to label resident cells 33 . Migration of antigen-presenting cells (APCs) from the lungs to dLN following IAV-PR8 infection was monitored by measuring the accumulation of CFSE + CD11c + cells in dLN ( Fig. 5a-c) . Although pulmonary APCs accumulated in dLN of WT mice 24 hours after IAV infection, the migration of APCs to dLN in Ifnlr1 −/− mice was significantly reduced (Fig. 5b,c) . We further assessed the accumulation of specific DC subsets in dLN, including inflammatory DCs (iDC), bulk conventional DCs (cDCs), CD4 + DCs, cross-presenting CD8α + DCs and CD103 + DCs, noting that the latter have been shown to take up antigen in the lung and migrate to dLN to effectively cross-present antigen for activation of CD8 + T cells 34, 35 . There was no difference in iDC migration between wild-type and Ifnlr1
mice, but we did observe a significant reduction in accumulation of cDCs in Ifnlr1 −/− compared to WT (Fig. 5e ). We found a significant reduction in migratory CD103 + DCs and cross-presenting CD8α
+ DCs in dLN of Ifnlr1 −/− mice following IAV infection (Fig. 5f,g ). These findings show that IFN-λ signaling is required for DC function and specific DC subset migration to dLN following IAV infection.
To determine whether CD103 + DC and CD8α + DC subsets were functionally and differentially dependent on IFN-λ or type I IFN signaling, we assessed the protein and mRNA levels of type I IFN receptor expression of each DC subset. In particular, CD103 + DCs have been described to be resistant to type I IFN signaling 36 , and so it can be postulated that CD103 + DC and CD8α + DC subsets might be dependent on IFN-λ signaling for their maturation, migration and antigen-presentation functions. Compared to iDCs that are known to respond to type I IFN, IFNAR1 protein levels were reduced on the surface of CD8α + DCs and CD103 + DCs found in dLN three days following IAV-PR8 infection (Fig. 5h) . We note that a reliable antibody or an immunoassay to detect IFN-λR1 on the surface of cells is not currently available; therefore, we utilized 
/CD11c
+ cells in dLN. a-c, Data from two pooled independent experiments are shown. n = 4 mice per group. d-g, WT and Ifnlr1 −/− mice were infected with 40 PFU PR8 i.n. and, 72 h post-infection, dLN were collected. The frequency and total number of the following DC populations in dLN were determined by flow cytometry utilizing the gating strategy in d. e, iDCs (CD3
. Data pooled from two independent experiments. n = 3 (Mock), 9 (WT IAV) or 7 (Ifnlr1 −/− IAV) mice per group. h, WT mice were infected with 40 PFU PR8 i.n. At 72 h post-infection dLN were collected and the expression of IFNAR on iDCs, CD8α + DCs and CD103 + DCs was determined by flow cytometry. MFI, mean fluoresence intensity. Two pooled independent experiments are shown. n = 5 mice per group. Bars show mean ± s.e.m. Significance determined using one-way ANOVA followed by Tukey's multiple comparisons test (a-h). i, iDCs and CD103
+ DCs were sorted from naïve lungs of WT mice, RNA was isolated and Ifnar1 and Ifnlr1 message was determined. Data from two individual mice are shown. ND, not detected. Bars show mean ± s.d. *P < 0.05, ** P < 0.01, ***P < 0.0001.
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+ DCs from the lungs of naïve mice express Ifnar1 mRNA, whereas Ifnlr1 mRNA expression was detected only in CD103 + DCs (Fig. 5i) . These results were similar to relative Ifnar1 and Ifnlr1 mRNA expression from lung CD103 
/CD11c
+ ) sorted from dLN of wild-type and Ifnlr1 −/− mice on day 4 following IAV infection. We chose this time point as it corresponded with DC accumulation from the lung to dLN to prime the CD8 + T cell response. This examination of DCs allowed identification of differentially expressed genes within the interface of innate and adaptive immunity that could impart function to program DC actions through response to IFN-λ (Fig. 6a) . A Venn diagram of significantly induced (upregulated) or suppressed (downregulated) genes showed overlapping and distinct genes amongst DCs from IAV-infected wild-type and Ifnlr1 −/− mice compared to mock-infected controls of each genotype (Fig. 6b) −/− DC on IAV infection in vivo (Fig. 6c) . This similar upregulation, of at least a subset of ISGs, suggested that it was not simply a defect in general and canonical interferon signaling that was driving the defect observed in Ifnlr1 −/− animals. Notably, the upper left quadrant of this scatter plot represented a divergent response of genes that were downregulated in wild-type DCs during IAV infection but upregulated in Ifnlr1
DCs. The genes in this quadrant that were highly upregulated in Ifnlr1
, but downregulated in wild type, included Loc101055769, Rgs9bp, Tmem246, Wdr31 and Il10. Analysis of genes involved in DC maturation also identified striking differences in transcriptional profiles in Ifnlr1 −/− compared to wild type (Fig. 6d) . For example, Il10, which was also identified as a gene whose expression was highly divergent between wild type and Ifnlr1 −/− , was of particular interest as the cytokine actions of IL-10 have recently been described to reduce CD8 + T cell antigen sensitivity and function in the context of chronic infection 38 . Further analyses revealed a noncanonical cell-mediated immune network of genes with IL-10 as a central regulatory hub in Ifnlr1 −/− cDCs from dLN (Fig. 6e) . Many genes in this network were not induced to statistical significance in wild-type cDCs in vivo, as indicated by white nodes indicating this network was largely silent during infection (Fig. 6e) . To determine whether the change in Il10 mRNA translated into a difference at the protein level, we infected wild-type and Ifnlr1 −/− BMDCs with IAV and assessed IL-10 concentration in culture supernatants. Although BMDCs from wild-type mice did not secrete detectable amounts of IL-10, IL-10 production and/or secretion was detected in Ifnlr1
BMDCs following IAV infection (Fig. 6f) , validating the transcriptional upregulation of Il10 to program an IL-10 response network in dLN cDCs from Ifnlr1 −/− mice. Overall, these data indicate that during IAV infection the cDCs in dLN undergo gene induction patterns that are dependent on IFN-λ signaling, and that IFN-λ signaling is essential for the negative regulation of IL-10 and its immunoregulatory network that links with aberrant CD8
+ T cell priming and responses during IAV infection.
IFN-λ signaling in CD11c
+ cells is required for the generation of pulmonary IAV-specific CD8 + T cells. (Fig. 7a) . Loss of IFN-λR1 specifically in CD11c + cells phenocopied global Ifnlr1 −/− mice, as we found a significant reduction in the IAV-specific CD8 + T cell response relative to wild-type controls (Fig. 7b) Fig. 5 ). Thus, IFN-λ signaling in DCs but not macrophages serves to direct their actions to program CD8 + T cells against IAV infection. Taken together, our study reveals an important requirement for IFN-λ signaling in programming DCs for activation, maturation and migration from lung to dLN during IAV infection to prime an optimal CD8 + T cell response that is required for effective immune memory and protection against heterosubtypic IAV infection ( Supplementary Fig. 6 ).
Discussion
Herein, we investigated the role of IFN-λ signaling in programming adaptive immune responses. In particular, we examined DC function and CD8 + T cell-mediated immunity that is key for clearance of IAV 41 . Our results highlight the critical function of IFN-λ signaling in DCs at the innate/adaptive immune interface required for activation, function and maintenance of IAV-specific CD8 + T cell responses critical for heterosubtypic IAV protection. Our studies reveal that IFN-λ signaling in DCs is essential for optimal antigen uptake and processing, upregulation of co-stimulatory molecules, regulation of IL-10 production by DCs, DC migration to dLN and CD8 + T cell activation. Intriguingly, we found that IFN-λ actions are specific to DC subsets (CD8α + DCs and CD103 + DCs) important for migration to dLN and regulation of CD8 + T cells in vivo during IAV infection.
Fig. 6 | IFN-λ signaling is essential for DC programming in dLN during IAV infection. a, WT and Ifnlr1
−/− mice were infected with 40 PFU PR8 or administered PBS i.n. and dLN were collected 96 h later. DCs were enriched using MACS separation and cDCs were sorted using the gating strategy shown in Fig. 5d . RNA was isolated and mRNA was prepared to perform mRNA sequencing. Following data cleanup, significant changes in gene expression for each genotype were determined compared to their respective mock-infected samples using limma package in R (threshold: log 2 fold change ≥ 1.5 and FDR ≤ 0.05) and plotted as shown. b, Venn diagram of genes up-or downregulated in cDC during IAV infection compared to mock-infected cDCs for each genotype. c, Scatter plots showing genes significantly changed in expression during infection for either genotype compared to their mock. Named genes in dark blue indicate ISGs. Il10 is highlighted in red. d, DC maturation genes significantly up-or downregulated compared to mock for either genotype were plotted in a heat map. Red, upregulated genes, blue, downregulated genes. e, A non-canonical cell-mediated immune network was identified in Ifnlr1 −/− samples and plotted. The same network is shown for WT cDCs. Red, upregulated genes, blue, downregulated genes, white, not significant. n = 3 samples from dLN of two mice pooled for each condition (a-e). f, WT and Ifnlr1 −/− BMDCs were infected with IAV at an MOI of 0.5 for 24 h. Supernatants were collected and IL-10 levels were determined by Luminex. n = 2 biological replicates from individual mice of one experiment representative of two independent experiments. Bars show mean ± s.d.
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However, multiple DC subsets are capable of priming IAV-specific CD4 + T cell responses 42, 43 , which likely explains why we observed similar effector CD4 . Unfortunately, specific and sensitive antibodies required to measure the surface expression of IFN-λR1 are currently unavailable, but our results indicate DCs are able to respond directly to IFN-λ3 (an IFN-λ subtype conserved in both mice and humans). We hypothesize that CD103 + DCs rely on IFN-λ signaling for optimal activation due to higher levels of IFN-λ receptor expression and their specific defect in cell migration to dLN during IAV infection in vivo in Ifnlr1 −/− compared to other DC subsets. This specific responsiveness of CD103 + DC subsets to IFN-λ signaling represents a novel potential target for development of IFN-λ-based adjuvants to IAV vaccination.
We identified IL-10 and an Il10 immunoregulatory gene network containing Rel and Il27 that was specifically activated in cDCs in Ifnlr1 −/− , distinct from canonical IFN signaling, and linked with the defective CD8 + T cell response against IAV infection in vivo. Rel/ NF-κB signaling in DC has been shown to lead to upregulation of IL-27 and subsequently IL-10, which performs an immunoregulatory function in shaping the CD4 + T cell repertoire 44 . Additionally, IL-10 has recently been shown to direct immunosuppressive actions to reduce CD8 + T cell activation and function in the context of chronic viral infection 38 , and IL-10 production from DCs was linked to T cell suppression in response to antitumor vaccination 45 . In the context of IAV infection, we propose a model in which IFN-λ signaling regulates and restricts IL-10 production in antigen crosspresenting CD103
+ DCs to facilitate optimal activation of CD8 + T cell responses that are critical for clearance of infection.
The aberrant/immunosuppressive function of CD103 + DCs and reduced CD8 + T cell responses in Ifnlr1 −/− mice during IAV infection ultimately culminated in enhanced mortality during heterosubtypic IAV re-challenge. This heterosubtypic IAV challenge model is dependent on CD8 + T cell responses for protection and mimics the mode of protection that can occur in the human population during the emergence of novel, recombined IAV strains, such as the pandemic H1N1 strain in 2009 (refs. 26, 46 ). In addition to this natural frequency of occurrence in the human population, the emerging threat of avian influenza IAV highlights the necessity for developing a comprehensive understanding of host factors that favor development of protective immunity. Given the importance of CD103 + DCs in delivery of IAV antigen for cross-priming of CD8 + T cell responses 30, 34, 35 , and the requirement for IFN-λ to impart DCs function, our results suggest IFN-λ could have application as an immune adjuvant to IAV vaccination. Future studies will focus on revealing the kinetics and requirements for development of CD8 ) mice per group. Bars show mean ± s.e.m. Significance was determined using unpaired two-sided t-test. *P < 0.05, **P < 0.01.
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Nature ImmuNology IAV challenge. Overall, our study highlights the important role of IFN-λ signaling to program an innate-adaptive immune interface in which an IFN-λ-DC-CD8 + T cell axis elicits protective adaptive immunity against IAV infection and exposure to re-emergent, heterosubtypic IAV.
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Methods
Specific details are listed below and in the Nature Research Reporting Summary.
Mice. Wild-type (WT) C57BL/6/J and Ifnar1
−/− mice were purchased from The Jackson Laboratory or bred in house from breeders obtained from The Jackson Laboratory. Ifnlr1 −/− mice were kindly provided by M. Diamond and maintained as a colony in the Gale laboratory 47 . The entire Ifnlr coding sequence is ablated in these mice 48 . Ifnlr1 fl/fl , Lyz2-cre and Itgax-cre mice were provided by H. Virgin and maintained in the Gale laboratory 39 . Briefly, these conditional-ready Ifnlr1 fl/fl mice contain two loxP sites around exon 2 of Ifnlr1. On expression of Cre-recombinase, the excision of this floxed site leads to a change in the amino acid sequence and a premature stop at amino acid 42 (ref. 39 ). Male and female mice were between the ages of 8 and 10 weeks at the onset of experiments. All experiments were performed according to approved Institutional Animal Care and Use Committee protocols at the University of Washington.
Viruses. All viruses were propagated in embryonated chicken eggs as previously described 49 . Viruses include A/PR/8/34, X31 (recombinant virus containing HA and NA from A/HK/1/68 and all other segments from PR8), PR8-GP 33 and PR8-2W. PR8 viruses expressing GP 33 (lymphocytic choreomeningitis virus) or 2W1S (from Salmonella typhimurium) epitopes were engineered into a site within the stalk of NA known to be tolerant to insertions 50 and generated as previously described 51 . The PR8-2W virus was utilized in experiments to evaluate T cell responses, as CD4 + T cells specific for the 2W1S epitope in C57Bl/6/J mice undergo a large expansion relative to other CD4 + T cell specificities 52 , allowing easier analysis of CD4 + T cell responses specifically activated by IAV infection.
Murine infections, tissue collection and processing. For all primary infection studies, mice were challenged with 40 PFU PR8, PR8-GP 33 or PR8-2W as noted in each figure legend. This dose of 40 PFU represents a commonly utilized infection dose that, in our model, leads to weight loss and development of clinical respiratory illness, but where all animals go on to recover from infection 30, 31 . For heterosubtypic re-challenge studies, mice were mock-infected or challenged with 40 PFU PR8 or X31. At 45 days following initial infection, animals were challenged with 2,000 PFU PR8. Mice were anesthetized using ketamine/xylazine and administered virus diluted in 50 μl PBS or administered 50 μl PBS alone for mock infections via intranasal administration 49 .
Virus titers. At designated times after infection, mice were euthanized, perfused with PBS and lungs were collected in 1 ml PBS + 0.5% BSA in Precellys tubes. Tissues were homogenized using a Precellys homogenizer. Samples were then centrifuged and supernatants aliquoted and snap frozen. Pulmonary virus titers were determined on frozen lung aliquots by plaque assay, as previously described 49 .
Preparation of samples for flow cytometry and acquisition of samples. At the designated times after infection, mice were euthanized and tissues were perfused with PBS by cardiac injection. Lungs and/or dLN were collected and single-cell suspensions were created by enzymatic digestion with type IV collagenase (Fisher/ Worthington) and DNase I (Sigma) and GentleMacs (Miltenyi) processing.
For flow cytometry staining, single-cell homogenates were blocked in 2% rat serum for 10 min at room temperature, incubated with specified antibodies for 30 min on ice, fixed with BD FACS Lysis buffer for 10 min at room temperature, resuspended in PBS and run on the LSRII (BD). Samples were analyzed using FlowJo software (BD).
The following anti-mouse antibodies conjugated to fluorochromes were utilized for flow cytometry: (company, clone) α-CD3ε (eBioscience/Invitrogen, 145-2C11), α-CD4 (Biolegend, GK1.5), α-CD8α (Biolegend, 53-6.7), α-CD11b BMDC generation, virus infection, sample collection and DQ-OVA. BMDCs were generated from WT and Ifnlr1 −/− bone marrow as previously described 53 . Briefly, bone marrow cells from WT and Ifnlr1 −/− mice were isolated and cultured for 7 d in complete RPMI-1640 (Gibco) containing 20 ng ml −1 GM-CSF (Peprotech) and 20 ng ml −1 IL-4 (Peprotech). BMDCs were infected at a multiplicity of infection (MOI) of 0.5 with PR8 in PBS containing Ca/Mg and 0.5% BSA for 1 h at 37 °C with rocking. Following infection, BMDCs were incubated in complete RPMI until collection. For real-time PCR analysis, samples were collected in RLT buffer and RNA was isolated using an RNeasy Extraction Kit (Qiagen). Complementary DNA was synthesized (Bio-Rad iScript Kit), and relative gene expression was determined by real-time PCR on a VIIA7 (Life Technologies) using the TaqMan Fast Advanced Master Mix (ThermoFisher) and primers specific for murine Ifnlr1 (ThermoFisher, Mm00558035_m1), murine Ifnar1 (ThermoFisher, Mm00439544_m1), murine Il10rb (ThermoFisher, Mm00434157_m1), murine Gapdh (ThermoFisher, Mm99999915_g1) and IAV NP (IDT). For IL-10 cytokine analysis, supernatants were collected and subsequent IL-10 levels were determined by multiplex immunoassay (Affymetrix Procartaplex).
For western blot analysis, BMDCs were stimulated with 500 ng ml
recombinant murine IFN-λ3 (R&D) or 10 ng ml −1 recombinant murine IFN-α2 (R&D) for 1 h, or 0.1, 1, 10 or 100 ng ml −1 recombinant murine IFN-λ3 (R&D) for 30 min. Following stimulation, cell pellets were collected in RIPA buffer (ThermoFisher) with 1× HALT protease/phosphatase inhibitor added (ThermoFisher). Samples were run on an SDS-PAGE gel, transferred to polyvinylidene difluoride and probed for phospho-STAT1 at site Y701 (Cell Signaling, 58D6), total STAT1 (Cell Signaling, no. 9172) and Actin (Cell Signaling, D6A8). For phospho-and total STAT1, α-rabbit HRP (Jackson ImmunoResearch) and SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher) were used and chemiluminescent signal detected on X-ray film. For Actin, α-rabbit AF680 (Jackson ImmunoResearch) or α-rabbit HRP (Jackson ImmunoResearch) was used to detect fluorescent signal on a LI-Cor Odyssey or chemiluminescent signal using a ChemiDoc XRS + (Bio-Rad). To determine ISG gene induction by BMDCs following stimulation, WT BMDCs were stimulated with 500 ng ml −1 recombinant murine IFN-λ3 (R&D) for 12 h. Following stimulation, samples were collected in RLT buffer and RNA was isolated using an RNeasy Extraction Kit (Qiagen). cDNA was sythensized (Bio-Rad iScript Kit) and relative gene expression was determined by real-time PCR on a VIIA7 (Life Technologies) using the SYBR Green Master Mix (ThermoFisher) and the following murine-specific primers (IDT): mChmp2a Fwd (5′-AGACGCC AGAGGAACTACTTC-3′), mChmp2a Rev (5′-ACCAGGTCTTTTGCCATGA TTC-3′), mIfi44 Fwd (5′-GTAACACAGCAATGCCTCTTGT-3′), mIfi44 Rev (5′-AACTGACTGCTCGCAATAATGT-3′), mIfit1 Fwd (5′-CTGAGATGTCACTT CACATGGAA-3′), mIfit1 Rev (5′-GTGCATCCCCAATGGGTTCT-3′), mIsg15 Fwd (5′-GGTGTCCGTGACTAACTCCAT-3'), mIsg15 Rev (5′-TGGAAAGGGTA AGACCGTCCT-3′), mOas3 Fwd (5′-TCTGGGGTCGCTAAACATCAC-3′) and mOas3 Rev(5′-GGCAATCCTTATCACTCTTGGTC-3′).
For the antigen uptake/processing assay, BMDCs were incubated with 10 μg ml -1 DQ-OVA (ThermoFisher) in PBS for 30 min, 1 h or 2 h at 37 °C or 2 h on ice as a control, as previously described 54 . For flow cytometric analysis, samples were collected at designated times post-infection or DQ-OVA administration and stained as described above.
Lung CFSE labeling for DC migration. Mice were anesthetized using ketamine/ xylazine and administered 8 mM CFSE (ThermoFisher) intranasally as previously described 55 . Shortly after CFSE administration mice were infected with PR8. At 24 h post-infection, lungs and dLN were collected and prepared for analysis by flow cytometry as described above.
Isolation of iDC and CD103
+ DCs for gene expression analysis. iDCs and CD103 + DCs were sorted from naïve lungs of WT mice using a FACS Aria with the gating strategy shown in Fig. 5d . RNA was collected from these cells and cDNA was amplified utilizing the Cells-to-ct kit (ThermoFisher) according to the manufacturer's instructions. Ifnar1 and Ifnlr message was determined by real-time PCR as described above. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
FlowJo (v10) was used for flow cytometric analysis. Prism GraphPad (7.0) was used for generation of graphs and statistical analysis. Code used for analysis of RNAseq data is available at https://hemann.galelab.org/ and programs used are FastQC (0.11.3), Bowtie2 (2.3.4), STAR (2.5.3a), ht-seq (0.6.1), R statistical programming language (3.4.3), bioconductor (3.4), limma bioconductor package (3.34.8), Spotfire (7.11.1), WGCNA bioconductor package (1.61), and gplots bioconductor package (3.0.1).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. The RNAseq data set is available on GEO under accession GSE124399 at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124399, and the markdown of our analysis of this data is available at https://hemann.galelab.org/.
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Sample size
Reasonable sample sizes were chosen based on preliminary results to ensure reproducibility of experiments and implement the "3 R's" in minimization of animal numbers.
Data exclusions None.
Replication
Experimental findings were reproduced in multiple experiments as described in the manuscript. For some figures, data from multiple experiments was pooled (as noted). Randomization Allocation of experimental groups was not randomized. Animals used for experiments were age and sex matched.
Blinding
Investigators were not blinded during this study as conclusions do not rely on subjective measures.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Validation
Commercially available flow cytometry antibodies were utilized at the concentration specified on the manufacturers website. All antibodies were validated using appropriate FMO/isotype controls for flow cytometry when applicable.
Commercially available primary antibodies for western blot were used at a concentration of 1:1000. Secondary antibodies were used at a concentration of 1:10000. Antibodies were validated by identification of specific signal at appropriate size (kDa).
All supporting documents can be found at manufacturers website.
Eukaryotic cell lines Policy information about cell lines
Cell line source(s)
MDCK cells were obtained from ATCC.
Authentication
No method for authentication was used.
Mycoplasma contamination
Cell are tested routinely for mycoplasma contamination by and are negative.
Commonly misidentified lines 
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
Wild animals WT C57Bl/6/J, Ifnar1-/-and Ifnlr1-/-mice were obtained from Jax and maintained via in-house breeding. For Cre x flox mice, Ifnlr1 floxed mice, Itgax-Cre, and Lyz2-Cre mice were obtained from Dr. Herbert W. Virgin, crossed, and maintained in-house. Male and female mice between the ages of 7 and 9 weeks were utilized for experiments according to approved IACUC protocols.
Study did not involve wild animals.
Field-collected samples
Study did not involve field-collected samples.
Ethics oversight
All animal experiments were conducted according to the animal use and care as specified on protocol #4158-09, which was reviewed and approved by the University of Washington Institutional Animal Care and Use Committee (IACUC). This protocol adheres to the recommendations in the Guide for the Care and Use of Laboratory Animals as adopted by the Office of Laboratory Animal Welfare in the National Institutes of Health.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
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The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
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Methodology Sample preparation
At the designated timepoints post infection, mice were euthanized, and tissues were perfused with PBS by cardiac injection.
